Looking for weight loss options? GLP-1 agonist medications, originally designed to manage type 2 diabetes, are now ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

Scouted selects products independently. If you purchase something from our posts, we may earn a small commission. Unless you ...

Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, ...

But one Cleveland Clinic expert is imploring executives not to look away. "Preventive measures are often neglected because they don't generate revenue, but they are incredibly important," Leslie Cho, ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Wall Street is bullish on Viking, but the company still has a lot to prove. Viking has a number of different clinical studies ...

Some outcomes, like reduced risk of cardiovascular disease and increased chance of nausea, were expected. But others took researchers by surprise.

surveys show — and now a major new study has revealed a long list of benefits and some little-known risks. Glucagon-like peptide-1 receptor (GLP-1) agonists — which contain either semaglutide ...

A/S, a global healthcare company specializing in diabetes care and other chronic conditions, has been at the forefront of the rapidly expanding GLP-1 market. With a market capitalization of $376.79 ...

In line with trial results, real-world data suggest GLP-1 receptor agonists have certain benefits in patients with moderate to severe chronic kidney disease (CKD).